Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

TADAWUL/4015 stock hub

TADAWUL/4015 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TADAWUL/4015is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

10.8B

Saudi Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

TADAWUL/4015

In the news

Latest news · TADAWUL/4015

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E20.1

P25 15.3P50 18.4P75 19.8

Trailing P/E22.7

P25 16.2P50 19.4P75 30.1

ROEn/a

P25 9.3P50 15.6P75 21.4

ROIC31.2

P25 7P50 12P75 21

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TADAWUL/4015 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

199

Groups with data

Currency

SAR

Showing 199 of 199 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Saudi Arabia
Country code	SA
Employees	1,255
Employees Change	126%
Employees Change Percent	11.16
Enterprise value	SAR 10.4B
Exchange	Saudi Stock Exchange
Financial currency	SAR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	SA15QGU1UNH6
Last refreshed	2026-05-10
Market cap	SAR 10.8B
Price	SAR 154
Price currency	SAR
Sector	Healthcare
Sic	2834
Symbol	tadawul/4015
Website	https://www.jamjoompharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	4.41%
EV Earnings	21.97x
EV/EBIT	20.87x
EV/EBITDA	19.19x
EV/FCF	28.89x
EV/Sales	6.85x
FCF yield	3.35%
Forward P/E	20.07x
P/B ratio	6.28x
P/E ratio	22.69x
P/S ratio	7.07x
PE Ratio3 Y	28.15x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	31.9%
EBITDA Margin	34.68%
FCF margin	23.7%
Gross margin	62.93%
Gross Profit	SAR 959.4M
Gross Profit Growth	14.35%
Gross Profit Growth Q	17.42%
Gross Profit Growth3 Y	16.51%
Net Income	SAR 475M
Net Income Growth	30.09%
Net Income Growth Q	31.9%
Net Income Growth Quarters	13%
Net Income Growth Years	4%
Net Income Growth3 Y	39.37%
Pretax Margin	33.08%
Profit Margin	31.16%
Profitable Years	8
Roa5y	12.24
Roe5y	20.81
ROIC	31.24
Roic5y	25.72

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-8.45%
EPS Growth	30.09
EPS Growth Q	31.9
EPS Growth Quarters	13
EPS Growth Years	4
EPS Growth3 Y	39.37
FCF Growth	71.09%
FCF Growth Q	29.03%
FCF Growth3 Y	35.12%
OCF Growth	54.31%
OCF Growth Q	31.05%
OCF Growth3 Y	21%
Revenue Growth	13.82x
Revenue Growth Q	17.28x
Revenue Growth Quarters	13x
Revenue Growth Years	4x
Revenue Growth3 Y	17.86x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	SAR 358.9M
Current Assets	SAR 1.2B
Current Liabilities	SAR 224.5M
Debt	SAR 16.4M
Debt EBITDA	SAR 0.03
Debt Equity	SAR 0.01
Debt FCF	SAR 0.05
Equity	SAR 1.7B
Interest Coverage	2,525.3
Net Cash	SAR 342.4M
Net Cash By Market Cap	SAR 3.18
Net Cash Growth	31.24%
Net Debt EBITDA	SAR -0.65
Net Debt Equity	SAR -0.2
Net Debt FCF	SAR -0.95
Tangible Book Value	SAR 1.7B
Tangible Book Value Per Share	SAR 24.28
WACC	6.03

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Working Capital Turnover	SAR 1.65

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend Growth	-12.28%
Dividend Growth Years	3%
Dividend per share	SAR 4
Dividend Years	4
Dividend Yield	2.6%
Ex Div Date	2026-03-02
Last Dividend	SAR 2
Payout Frequency	Semi-Annual
Payout Ratio	50.99%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-8.44%
200-day SMA	149.2
50-day SMA	145.7
50-day SMA vs 200-day SMA	50under200
All Time High	202.4
All Time High Change	-23.91%
All Time High Date	2024-09-19
All Time Low	66
All Time Low Change	133.33%
All Time Low Date	2023-06-20
ATR	2.69
Beta	0.33
Beta1y	0.35
Beta2y	0.25
Ch YTD	8.22
High	154.4
High52	183.8
High52 Date	2025-05-12
High52ch	-16.21%
Low	151.8
Low52	125
Low52 Date	2026-03-01
Low52ch	23.2%
Ma50ch	5.71%
Price vs 200-day SMA	3.23%
RSI	56.49
RSI Monthly	56.8
RSI Weekly	0
Sharpe ratio	-0.38x
Sortino ratio	-0.33
Total Return	2.6%
Tr YTD	9.87
Tr1m	2.6%
Tr1w	-0.9%
Tr3m	17.2%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	SAR 486.3M
Operating Income Growth	22.51
Operating Income Growth Q	17.98
Operating Income Growth3 Y	25.14
Operating margin	31.9

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	24,179,777%
Net Borrowing	-946,218
Shares Insiders	65.46%
Shares Institutions	3.23%
Shares Out	70,000,000
Shares Qo Q	0%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	SAR 361.2M
Average Volume	33,870.6x
Bv Per Share	24.53
CAPEX	SAR -53M
Ch1m	2.6
Ch1w	-0.9
Ch1y	-10.88
Ch3m	15.44
Ch6m	2.46
Change	1.32%
Change From Open	1.45
Close	152
Days Gap	-0.13
Depreciation Amortization	41,994,094
Dollar Volume	6,272,420
Earnings Date	2026-07-23
EBIT	SAR 486.3M
EBITDA	SAR 528.6M
EPS	SAR 6.79
F Score	3
FCF	SAR 361.2M
FCF EV Yield	3.46x
FCF Per Share	SAR 5.16
Financing CF	-282,940,218
Fiscal Year End	December
Founded	1,994
Graham Number	61.19275
Graham Upside	-60.26
Income Tax	SAR 29.3M
Investing CF	-59,116,968
Is Primary Listing	1
Last Earnings Date	2026-02-24
Last Report Date	2025-12-31
Lynch Fair Value	SAR 170
Lynch Upside	10.16
Ma150	146.1
Ma150ch	5.42%
Ma20	154.7
Ma20ch	-0.47%
Net CF	68,620,293
Next Earnings Date	2026-07-23
Open	151.8
P FCF Ratio	29.84
P OCF Ratio	26.02
Payment Date	2026-03-15
Position In Range	84.62
Ppne	718,476,032
Price Date	2026-05-07
Price EBITDA	SAR 20.39
Ptbv Ratio	6.34
Relative Volume	1.2x
Revenue	1,524,486,461x
Tax By Revenue	1.92x
Tax Rate	5.8%
Tr6m	4.02%
Volume	40,730

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

TADAWUL/4015 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+2.6%

$4.00 annual per share

Payout ratio

+51.0%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

3 consecutive years of growth

Total shareholder yield

+2.6%

Next ex-dividend date: 2026-03-02

Performance

TADAWUL/4015 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TADAWUL/4015?

Insider, institutional, and short-interest positioning.

Institutional ownership

+3.2%

Share of float held by funds and institutions

Insider ownership

+65.5%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

n/a

Negative means the company is buying back shares.

Technical

TADAWUL/4015 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

56.5

Neutral momentum band

Price vs 200-day MA

+3.2%

50/200-day relationship not available

Beta (5Y)

0.33

Less volatile than the market

Sharpe ratio

-0.38

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TADAWUL/4015

Hub-level FAQ points readers to the deeper analysis pages.

What is the current tadawul/4015 stock rating?

tadawul/4015 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full tadawul/4015 analysis?

The full report lives at /stocks/tadawul/4015/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for tadawul/4015?

The latest report frames tadawul/4015 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the tadawul/4015 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.